S. Silva

ORCID: 0000-0002-2084-9541
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health, Nursing, Elderly Care
  • Public Health in Brazil
  • Renal Transplantation Outcomes and Treatments
  • Chronic Lymphocytic Leukemia Research
  • Migraine and Headache Studies
  • Culinary Culture and Tourism
  • Cytomegalovirus and herpesvirus research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Dental Implant Techniques and Outcomes
  • Heavy Metal Exposure and Toxicity
  • Dental Health and Care Utilization
  • Trace Elements in Health
  • Organ Transplantation Techniques and Outcomes
  • Electrospun Nanofibers in Biomedical Applications
  • Amazonian Archaeology and Ethnohistory
  • Sexual Differentiation and Disorders
  • Periodontal Regeneration and Treatments
  • Organ Donation and Transplantation
  • Attention Deficit Hyperactivity Disorder
  • X-ray Spectroscopy and Fluorescence Analysis
  • Healthcare Regulation
  • Healthcare during COVID-19 Pandemic
  • Transcranial Magnetic Stimulation Studies
  • Fluoride Effects and Removal
  • Indigenous Health and Education

Universidade Federal de São Paulo
2023

Hospital de Santa Maria
1990-2017

Centro Hospitalar Lisboa Norte
2013-2017

Introduction: Bruton's tyrosine kinase inhibitor, ibrutinib, was recently approved for treatment-naïve, relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia (CLL). Discrepancies between clinical trials routine healthcare are commonly observed in hematology–oncology. We aimed to evaluate the real-world characteristics drug-related toxicities of patients with CLL treated ibrutinib Portugal. Methods: conducted a multicenter (13 institutions) retrospective observational...

10.1002/hon.2439_146 article EN Hematological Oncology 2017-06-01

10.1016/0168-583x(90)90240-u article EN Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms 1990-04-01

ABSTRACT Objective: Verify the clinical efficacy and safety of a low-cost tDCS device, in trial for major depressive disorder. Methods: 168 persons were recruited; 32 depressed individuals with moderate or severe symptoms (HDRS17 scores higher than 18) included randomized (16 each group). The intervention consisted 10 active anodal sessions at 2 mA 30 minutes over left dorsolateral prefrontal cortex; sham. main outcome was HDRS17; secondary outcomes satisfaction (TSQM II) quality life...

10.1590/0047-2085000000429 article EN cc-by Jornal Brasileiro de Psiquiatria 2023-01-01
Coming Soon ...